VERU — Veru Inc.

Summary of Veru Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $15.7 million, or $1.07 per diluted share, improved from a net loss of $35.3 million, or $2.61 per diluted share, in the previous year.
• Net Loss from Discontinued Operations: $7 million, including a $4.1 million loss on the sale of the FC2 Female Condom business.
• Cash Position: As of September 30, 2025, cash and equivalents stood at $15.8 million, down from $24.9 million the previous year. Following a public offering on October 31, 2025, the company raised approximately $23.4 million.
• R&D Expenses: Increased to $15.6 million from $12.8 million, primarily due to the Phase IIb QUALITY clinical study for enobosarm.
• SG&A Expenses: Decreased to $19.9 million from $24.6 million, attributed to lower share-based compensation.

2. Strategic Updates and Business Highlights

• Product Development Focus: Veru is concentrating on two key assets: enobosarm (a muscle-preserving agent for obesity treatment) and sabizabulin (an anti-inflammatory for cardiovascular disease).
• Phase IIb QUALITY Study Results: Enobosarm demonstrated 100% preservation of lean mass and greater fat loss when combined with semaglutide, showing a promising safety profile.
• Regulatory Guidance: The FDA provided clarity on regulatory pathways for enobosarm, indicating that both incremental weight loss and preservation of physical function could be acceptable endpoints for approval.
• Upcoming Phase IIb PLATEAU Study: Targeting older patients (aged 65+) with obesity to assess the ability of enobosarm to overcome weight loss plateaus associated with GLP-1 treatments.

3. Forward Guidance and Outlook

• Clinical Trials: The Phase IIb PLATEAU clinical trial is set to begin in Q1 2026, with an interim analysis expected in Q1 2027.
• Funding: The recent public offering provides sufficient capital to support operations through the interim analysis of the upcoming study.
• Market Potential: The company aims to address a significant market need for effective obesity treatments, particularly among older patients.

4. Challenges and Points of Concern

• Cash Burn: The company reported a cash burn of $30 million for operating activities, indicating ongoing financial pressures.
• Dependence on Future Trials: Success in upcoming clinical trials is critical, as the company is not yet profitable and will require additional capital for continued operations.
• Competitive Landscape: Other companies are also advancing similar treatments, which could pose competitive pressures in the obesity treatment market.

5. Notable Q&A Insights

• GLP-1 Receptor Agonists: CEO Mitchell Steiner clarified that the Phase IIb PLATEAU study will focus on one GLP-1 agent (either tirzepatide or semaglutide) to minimize variability.
• Regulatory Flexibility: There is potential flexibility in regulatory discussions regarding endpoints, with the FDA allowing for functional improvements to be considered alongside weight loss.
• Target Population: The focus on patients over 65 is strategic, aiming to address those most in need of effective obesity treatments while also aligning with regulatory guidance.

Overall, Veru Inc. is positioned to advance its clinical programs with a focus on innovative obesity treatments, although it faces financial challenges and competitive pressures in the biopharmaceutical landscape.